Trial Profile
Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Diastolic heart failure; Left ventricular dysfunction; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms DILATE; DILATE-1
- Sponsors Bayer
- 27 Sep 2013 Primary endpoint 'Pulmonary-artery-pressure' has not been met.
- 27 Sep 2013 New trial record
- 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.